This preprint is under consideration at BMC Research Notes. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research note
Safar Farajnia
Tabriz University of Medical Sciences Drug Applied Research Center
Corresponding Author
ORCiD: https://orcid.org/0000-0002-6087-9147
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Objective
Uncoupling protein 2 (UCP2) is a regulator of insulin secretion, free fatty acid (FFA) concentrations and lipid metabolism that plays crucial roles in energy homeostasis. Last decade reports have described close association between UCP2 polymorphisms and nonalcoholic fatty liver disease (NAFLD) and diabetes mellitus type 2 (T2DM).
Results
A higher prevalence of insertion/insertion genotype has been observed in T2DM patients compared with the control group (p value˂ 0.05). But, there was no difference in genotype distribution between NAFLD patients and control groups (p value > 0.05). NAFLD patients with D/D, D/I genotype had higher triglyceride, ALT and AST levels, and lower HDL level than healthy controls. Patients with T2DM together with D/D or D/I genotype also had significantly higher fasting serum glucose (FSG) level. While we found association between the 45 bp I/D polymorphism in 3ʹUTR of UCP2 and T2DM, existence of correlation between this polymorphism and NAFLD was not identified.
Keywords
UCP2, 45bp I/D polymorphism, NAFLD, T2DM
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
The most recent version of this article is available here.
No community comments so far
Editorial decision: Major revision
On 13 Mar, 2021
Review #1 received
Received 17 Feb, 2021
Reviewers invited
Invitations sent on 09 Jan, 2021
Reviewer #1 agreed
On 09 Jan, 2021
Editor assigned
On 26 Nov, 2020
Submission checks complete
On 26 Nov, 2020
Editor invited
On 26 Nov, 2020
No comments provided
Editorial decision: Minor revision
On 01 Nov, 2020
Review #2 received
Received 08 Oct, 2020
Reviewer #2 agreed
On 28 Sep, 2020
Review #1 received
Received 26 Sep, 2020
Reviewers invited
Invitations sent on 25 Sep, 2020
Reviewer #1 agreed
On 25 Sep, 2020
Editor assigned
On 21 Sep, 2020
Submission checks complete
On 20 Sep, 2020
Editor invited
On 20 Sep, 2020
Version 1
Posted 08 Jul, 2020
No comments provided
Editorial decision: Major revision
On 27 Jul, 2020
Review #2 received
Received 21 Jul, 2020
Review #1 received
Received 15 Jul, 2020
Reviewer #2 agreed
On 11 Jul, 2020
Editor assigned
On 09 Jul, 2020
Reviewers invited
Invitations sent on 09 Jul, 2020
Reviewer #1 agreed
On 09 Jul, 2020
Submission checks complete
On 07 Jul, 2020
Editor invited
On 07 Jul, 2020
First submitted
On 05 Jul, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Pediatrics
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
This preprint is under consideration at BMC Research Notes. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research note
Safar Farajnia
Tabriz University of Medical Sciences Drug Applied Research Center
Corresponding Author
ORCiD: https://orcid.org/0000-0002-6087-9147
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
The most recent version of this article is available here.
No community comments so far
Editorial decision: Major revision
On 13 Mar, 2021
Review #1 received
Received 17 Feb, 2021
Reviewers invited
Invitations sent on 09 Jan, 2021
Reviewer #1 agreed
On 09 Jan, 2021
Editor assigned
On 26 Nov, 2020
Submission checks complete
On 26 Nov, 2020
Editor invited
On 26 Nov, 2020
No comments provided
Editorial decision: Minor revision
On 01 Nov, 2020
Review #2 received
Received 08 Oct, 2020
Reviewer #2 agreed
On 28 Sep, 2020
Review #1 received
Received 26 Sep, 2020
Reviewers invited
Invitations sent on 25 Sep, 2020
Reviewer #1 agreed
On 25 Sep, 2020
Editor assigned
On 21 Sep, 2020
Submission checks complete
On 20 Sep, 2020
Editor invited
On 20 Sep, 2020
Version 1
Posted 08 Jul, 2020
No comments provided
Editorial decision: Major revision
On 27 Jul, 2020
Review #2 received
Received 21 Jul, 2020
Review #1 received
Received 15 Jul, 2020
Reviewer #2 agreed
On 11 Jul, 2020
Editor assigned
On 09 Jul, 2020
Reviewers invited
Invitations sent on 09 Jul, 2020
Reviewer #1 agreed
On 09 Jul, 2020
Submission checks complete
On 07 Jul, 2020
Editor invited
On 07 Jul, 2020
First submitted
On 05 Jul, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Pediatrics
License:
This work is licensed under a CC BY 4.0 License. Read Full License
The most recent version of this article is available here.
Objective
Uncoupling protein 2 (UCP2) is a regulator of insulin secretion, free fatty acid (FFA) concentrations and lipid metabolism that plays crucial roles in energy homeostasis. Last decade reports have described close association between UCP2 polymorphisms and nonalcoholic fatty liver disease (NAFLD) and diabetes mellitus type 2 (T2DM).
Results
A higher prevalence of insertion/insertion genotype has been observed in T2DM patients compared with the control group (p value˂ 0.05). But, there was no difference in genotype distribution between NAFLD patients and control groups (p value > 0.05). NAFLD patients with D/D, D/I genotype had higher triglyceride, ALT and AST levels, and lower HDL level than healthy controls. Patients with T2DM together with D/D or D/I genotype also had significantly higher fasting serum glucose (FSG) level. While we found association between the 45 bp I/D polymorphism in 3ʹUTR of UCP2 and T2DM, existence of correlation between this polymorphism and NAFLD was not identified.
Loading...